A multifunctional nanogel encapsulating layered double hydroxide for enhanced osteoarthritis treatment via protection of chondrocytes and ECM

Osteoarthritis (OA) is characterized by progressive and irreversible damage to the articular cartilage and a consecutive inflammatory response. However, the majority of clinical drugs for OA treatment only alleviate symptoms without addressing the fundamental pathology. To mitigate this issue, we de...

Full description

Saved in:
Bibliographic Details
Published in:Materials today bio Vol. 26; p. 101034
Main Authors: Liu, Changxing, Sun, Yawei, Li, Dengju, Wang, Fan, Wang, Haojue, An, Senbo, Sun, Shui
Format: Journal Article
Language:English
Published: England Elsevier Ltd 01.06.2024
Elsevier
Subjects:
Chondrocytes
Extracellular matrix
Full Length
Layered double hydroxide (LDH)
Osteoarthritis
Strontium (Sr2+)
Tannic acid
Tannic acid
Extracellular matrix
Strontium (Sr2+)
Layered double hydroxide (LDH)
Osteoarthritis
Chondrocytes
ISSN:2590-0064, 2590-0064
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Osteoarthritis (OA) is characterized by progressive and irreversible damage to the articular cartilage and a consecutive inflammatory response. However, the majority of clinical drugs for OA treatment only alleviate symptoms without addressing the fundamental pathology. To mitigate this issue, we developed an inflammation-responsive carrier and encapsulated bioactive material, namely, LDH@TAGel. The LDH@TAGel was designed with anti-inflammatory and antioxidative abilities, aiming to directly address the pathology of cartilage damage. In particular, LDH was confirmed to restore the ECM secretion function of damaged chondrocytes and attenuate the expression of catabolic matrix metalloproteinases (Mmps). While TAGel showed antioxidant properties by scavenging ROS directly. In vitro evaluation revealed that the LDH@TAGel could protect chondrocytes from inflammation-induced oxidative stress and apoptosis via the Nrf2/Keap1 system and Pi3k-Akt pathway. In vivo experiments demonstrated that the LDH@TAGel could alleviated the degeneration and degradation of cartilage induced by anterior cruciate ligament transection (ACLT). The OARSI scores indicating OA severity decreased significantly after three weeks of intervention. Moreover, the IVIS image revealed that LDH@TAGel enhances the controlled release of LDH in a manner that can be customized according to the severity of OA, allowing adaptive, precise treatment. In summary, this novel design effectively alleviates the underlying pathological causes of OA-related cartilage damage and has emerged as a promising biomaterial for adaptive, cause-targeted OA therapies. [Display omitted] •The novel LDH@TAGel was developed for drug-free therapies of osteoarthritis.•The LDH@TAGel has anti-inflammatory effects and safeguards chondrocytes.•The LDH@TAGel counters oxidative stress via Nrf2/Keap1 system.•The LDH@TAGel inhibits cell apoptosis via the PI3K-AKT pathway.•The LDH@TAGel possess the release behavior adapts to inflammation severity.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
C. Liu and Y. Sun contributed equally to this work.
ISSN:2590-0064
2590-0064
DOI:10.1016/j.mtbio.2024.101034